Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
A Rodriguez-VidaB P ValderramaD CastellanoA PintoB MelladoJ PuenteM A ClimentM DomenechF VazquezJ L Perez-GraciaT BonfillR Morales-BarreraE Gonzalez-BillalabeitiaX Garcia-Del-MuroP MarotoN Navarro-GorroN JuanpereO JuanJ BellmuntPublished in: ESMO open (2024)
The hypothesis that induction avelumab could enhance the efficacy of subsequent ChT was not proven. Administering IO alone as induction before ChT is not an adequate strategy.